These molecules can bind two targets, TfR1 for RMT and HER2, for prospective targeting to HER2+ brain tumors while maintaining the Fc domain unchanged, allowing for beneficial FcRn recycling [280]. This evidence concerns the gene TFRC and brain neoplasm.